6 key facts about JAK inhibitors
Janus kinase inhibitors, known as JAK inhibitors or jakinibs, are increasingly used in rheumatology.
In Australia, two such drugs are PBS listed: tofacitinib (Pfizer, Xeljanz) and baricitinib (Eli Lilly, Olumiant).
Both are indicated for severe active rheumatoid arthritis and must be prescribed by a suitable specialist.
But what are these drugs, how do they work, and what adverse effects can they cause?